Partnership between leading pharmaceutical
solution providers enhances offerings across pharmaceutical
development and commercialization
KATY,
Texas, Aug. 13, 2024 /PRNewswire/ --
ToxStrategies, a leading multidisciplinary scientific consulting
firm, today announced the acquisition of Suttons Creek. Founded in
2012 by Steven Badelt, PhD, Suttons Creek offers comprehensive
consulting and execution services for combination product
development across each phase of the product lifecycle. These
product development services include quality, regulatory, human
factors and usability engineering, strategy consulting, training
and education, and corporate readiness and executive advising.
ToxStrategies is a portfolio company of Renovus Capital Partners.
Terms of the transaction were not disclosed.
![Renovus Capital Partners (PRNewsfoto/Renovus Capital Partners) Renovus Capital Partners (PRNewsfoto/Renovus Capital Partners)](https://mma.prnewswire.com/media/1985057/Renovus_Capital_Partners_Logo.jpg)
ToxStrategies partnered with Renovus in November 2022 with the goal of expanding its
existing client base and developing new end markets. The
acquisition of Suttons Creek by ToxStrategies brings together two
best-in-class firms within the life sciences industry, with a
unified focus on providing integrated teams to solve the
multifaceted problems and challenges faced by its clients,
particularly in the drug development arena. Steven Badelt will continue to lead Suttons
Creek as a Division of ToxStrategies.
Suttons Creek includes a staff of globally experienced, highly
specialized consultants with deep knowledge of all aspects of
combination product development and deployment through the complex
regulatory approval process. They have a proven track record of
creating successful pathways to global regulatory approval and
commercialization of combination products. Their team of experts
has the know-how to integrate the device-related aspects of
combination products into any phase of pharmaceutical development
and commercialization. With client business goals in mind, Suttons
Creek creates adaptive strategies and customized processes for
faster entry to the market.
"We are excited to welcome the Suttons Creek engineers,
scientists, and regulatory specialists to our growing team of
consultants," said ToxStrategies President Dr. Laurie Couture Haws, PhD, DABT, ATS. "These
experts work to assist clients in the pharmaceutical and medical
device industries with the safety assessment, regulatory approval,
commercialization, and transport of new, life-changing therapies
and treatments. The Suttons Creek team expands and complements our
current capabilities to include drug and biologic delivery systems.
Suttons Creek offers expert-managed services and consulting that
align with ToxStrategies' mission of delivering unparalleled
technical excellence to address our clients' needs, with a spirit
of collaboration and passion for advancing science."
Steven Badelt added, "Suttons
Creek started with the goal of providing the best available managed
services and consulting on combination products in the
pharmaceutical industry. We sought a partner organization that
would offer expertise and investment support for scaling while
continuing our unwavering commitment to client success…and we found
that partner in ToxStrategies! The combination of our enterprises
is now fueled by the expertise in scaling provided by Renovus and
supported by the culture of ToxStrategies, with their
vision of technical excellence and advancing science, as
stated by Dr. Haws. This move will allow us to offer a broader
portfolio of solutions to clients as we grow to lead the industry
in providing managed services for combination products and
beyond."
"ToxStrategies has generated significant momentum over the last
year in terms of adding new service offerings to its life sciences
practice," said Jesse Serventi, a
founding partner at Renovus Capital Partners. "We are thrilled to
welcome Suttons Creek into the fold, bringing deep regulatory
expertise to the medical device, pharmaceutical, and combination
products industries. We are confident that this acquisition will
allow ToxStrategies to deliver even more value to its clients and
provide numerous growth opportunities for the company."
About ToxStrategies
ToxStrategies, a family of
companies that includes Modality Solutions and Clintrex Research,
is a multidisciplinary scientific consulting firm with deep
expertise in all areas of toxicology (from in vivo and in
vitro studies, to application of new approach methods and
computational toxicology, to human exposure assessment), as well as
in epidemiology, industrial hygiene, and the science of therapeutic
product development (drugs, biologics, devices), including
nonclinical and human research and management of product supply
chains. The ToxStrategies team includes toxicologists,
epidemiologists, physicians, industrial hygienists, health
economics and outcomes researchers, engineers, exposure scientists,
computational scientists, biostatisticians, information
specialists, and regulatory specialists. These scientists are
recognized as leaders in their respective disciplines, and they
bring a high level of technical expertise to every project.
ToxStrategies is headquartered in Texas and has offices and remote consultants
throughout the US, Canada, and
England. For more information,
please visit www.toxstrategies.com.
About Suttons Creek
Suttons Creek serves as the
combination product and device team for the pharmaceutical
industry. The company's full-service model has successfully
supported the development of more than 120 individual drug and
biologic delivery systems, including Auto Injectors,
Pre-Filled Syringes, Infusion Pumps, On-Body Devices, Inhalers,
Lyo-Kits, Attached Bio-Sensors, Vial Adaptors, SaMD Adherence
Support, and Cell and Gene Therapy Delivery Systems. They provide
executive-level strategic advising, as well as organizational
development and training services. The team includes expertise
direct from the FDA, pharma, and device and component vendors in
the combination product domain. These specialists have proven
credibility after leading more than 70 large and small pharma
companies to global combination product success. Suttons Creek has
been engaging with pharma companies since before the FDA's
combination product ruling, uniquely positioning them as the pharma
industry's premier device and connectivity team. With a roster of
globally experienced, specialized consultants, Suttons Creek
supports clients with consulting and managed services from concept
to deployment through the complex regulatory approval process. For
more information, please visit www.suttonscreek.com.
About Renovus Capital Partners
Founded in 2010,
Renovus Capital Partners is a lower middle-market private equity
firm specializing in the Knowledge and Talent industries. From its
base in the Philadelphia area,
Renovus manages over $1.5 billion across its three sector-focused
funds and other strategies. The firm's current portfolio includes
more than 25 U.S.-based businesses that specialize in education and
training, healthcare services, technology services, and
professional services. Renovus typically partners with founder-led
businesses, building on its experience within the industry and
access to debt and equity capital to make operational improvements,
recruit top talent, pursue add-on acquisitions, and oversee
strategic growth initiatives. Visit us at www.renovuscapital.com
and follow us on LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/toxstrategies-acquires-suttons-creek-302220223.html
SOURCE Renovus Capital Partners LLC